ClinicalTrials.Veeva

Menu

Study of Colonization of Strains L.Plantarum and L.Brevis in the Product AB-DENTALAC Chewing Gum (AB-GUM-2016)

A

AB Biotics

Status

Completed

Conditions

Periodontal Disease

Treatments

Dietary Supplement: AB-DENTALAC [Probiotics (study)]
Dietary Supplement: Placebo (control)

Study type

Interventional

Funder types

Industry
Other

Identifiers

NCT03540498
AB-GUM-2016

Details and patient eligibility

About

Study will follow a randomized, double-blind, placebo-controlled design with two groups in parallel,N of 40 patients in 6 weeks of follow up for the evaluation of two different posology models (daily consumption of probiotic gum, with or without previous professional oral cleaning). Probiotics have recently been used to combat oral diseases (plaque control, caries, halitosis, etc.), as a non-invasive natural therapy.

Full description

The study will follow a randomized, double-blind, placebo-controlled design with two groups in parallel, for the evaluation of two different posology models (daily consumption of probiotic gum, with or without previous professional oral cleaning). Probiotics have recently been used to combat oral diseases (plaque control, caries, halitosis, etc.), as a non-invasive natural therapy.

The aim of this study is to assess whether the daily consumption of AB-DENTALAC gum allows the colonization of strains L.plantarum KABP051 (CECT7481) and L.brevis KABP052 (CECT7480) in the oral microbiota, and to confirm the absence of side effects, with the following setup:

  1. Number of patients to be randomized:40
  2. Number of visits per patient: 2

The study will determine the index of plaque and gingival index as a measure of oral health. The presence of Lactobacillus in the samples collected by qPCR will also be quantified.

The patient will benefit from a buccal revision and control by a periodontist for 6 weeks. It will also help subsequent patients to obtain a better treatment (if the results are significant). No harm is expected to participate, it is a minimal risk study, with non-invasive exploratory tests and a product suitable for human consumption and marketed in Europe since 2012.

The potential patients to participate in the study will be healthy patients, so if they do not wish to participate they will not need alternative treatment. The objective of the study is to see if the probiotic is able to colonize the mouth in healthy patients, it is not a study to demonstrate the effectiveness of the product.

If there is any serious adverse effect (something totally unexpected being a product with probiotic strains QPS), the patient will be advised to stop taking the product immediately. It is not anticipated that the use of any additional treatment is necessary.

The promoter will provide all the necessary material for the study: 60 cases of placebo chewing gum, 60 cases of probiotic chewing gum, and cleaning material (toothbrush and fluoridated toothpaste) for all patients.

Statistical analysis of bacterial colonization will be performed using Student's T with logarithmic transformation of data if required, considering a two-tailed P <0.05 as significance cut-off.

Enrollment

40 patients

Sex

All

Ages

18 to 55 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Women and men between 18-55 years.
  • Capacity to understand the procedures and implications of the study.
  • Gingival Index <1,5 (Löe and Silness, Acta Odontol Scand. 1963. 21:533-51)
  • Plaque Index <2,0 (Löe and Silness, Acta Odontol Scand. 1963. 21:533-51)
  • Periodontal pocket depth <5 mm

Exclusion criteria

  • Less than 20 natural teeth
  • More than 2 untreated caries at the time of enrollment
  • Current orthodontic or periodontal treatment
  • Hypersensitivity or allergy to any of the ingredients of the experimental product
  • Consumption of antibiotics in the 8 weeks prior to treatment
  • Use of probiotics designed to improve oral health, or having consumed them during the 8 weeks prior to the study
  • Consumption of any type of probiotic during the 4 weeks prior to the study
  • Usual consumption of clorhexidine or other mouthwashes with bactericidal active ingredients during the 30 days before the start of the study
  • Pregnant or lactating women
  • Participants with chronic diseases (eg, diabetes, kidney problems, cancer) or under chronic treatment

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

40 participants in 2 patient groups, including a placebo group

Probiotics
Experimental group
Description:
The volunteers will follow the assigned treatment for 6 weeks (PROBIOTICS_AB-DENTALAC CHEWING GUM. Orally) , which will consist of the consumption of 2 chewing gums a day. The chewing gum should be chewed for at least 15-20 minutes at least 1 hour after the consumption of food. For at least 1 hour after the consumption of chewing gum, volunteers will not be able to consume food, drink (except water) or clean their teeth. Adherence to the treatment will be made by returning the empty containers after 6 weeks.
Treatment:
Dietary Supplement: AB-DENTALAC [Probiotics (study)]
Control
Placebo Comparator group
Description:
The volunteers will follow the assigned treatment for 6 weeks (PLACEBOS CHEWING GUM. Orally) , which will consist of the consumption of 2 chewing gums a day. The chewing gum should be chewed for at least 15-20 minutes at least 1 hour after the consumption of food. For at least 1 hour after the consumption of chewing gum, volunteers will not be able to consume food, drink (except water) or clean their teeth. Adherence to the treatment will be made by returning the empty containers.
Treatment:
Dietary Supplement: Placebo (control)

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems